CN111107871A - 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途 - Google Patents

抗原呈递合成表面、共价官能化表面、活化t细胞及其用途 Download PDF

Info

Publication number
CN111107871A
CN111107871A CN201880058921.XA CN201880058921A CN111107871A CN 111107871 A CN111107871 A CN 111107871A CN 201880058921 A CN201880058921 A CN 201880058921A CN 111107871 A CN111107871 A CN 111107871A
Authority
CN
China
Prior art keywords
cells
antigen
molecule
activating
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880058921.XA
Other languages
English (en)
Chinese (zh)
Inventor
P·J·比米勒
A·J·马斯特罗扬尼
S·N·裴
Jr·R·D·洛
A·莫恰罗
K·D·卢瑟贝克
Y·布罗涅维特斯凯
G·K·斯塔德勒
A·W·麦克法兰
K·T·查普曼
D·史密斯
N·C·马克斯
A·L·古德塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bruker Cellular Analysis Inc
Original Assignee
Berkeley Lights Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berkeley Lights Inc filed Critical Berkeley Lights Inc
Priority to CN202410633579.9A priority Critical patent/CN118846017A/zh
Publication of CN111107871A publication Critical patent/CN111107871A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502769—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements
    • B01L3/502784—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements specially adapted for droplet or plug flow, e.g. digital microfluidics
    • B01L3/502792—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements specially adapted for droplet or plug flow, e.g. digital microfluidics for moving individual droplets on a plate, e.g. by locally altering surface tension
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Clinical Laboratory Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
CN201880058921.XA 2017-07-21 2018-07-20 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途 Pending CN111107871A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410633579.9A CN118846017A (zh) 2017-07-21 2018-07-20 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762535742P 2017-07-21 2017-07-21
US62/535,742 2017-07-21
US201862660779P 2018-04-20 2018-04-20
US62/660,779 2018-04-20
US201862664279P 2018-04-30 2018-04-30
US62/664,279 2018-04-30
PCT/US2018/043146 WO2019018801A1 (en) 2017-07-21 2018-07-20 SYNTHETIC SURFACES FOR PRESENTING ANTIGENS, COVALENTLY FUNCTIONALIZED SURFACES, ACTIVATED T CELLS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410633579.9A Division CN118846017A (zh) 2017-07-21 2018-07-20 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途

Publications (1)

Publication Number Publication Date
CN111107871A true CN111107871A (zh) 2020-05-05

Family

ID=65015614

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880058921.XA Pending CN111107871A (zh) 2017-07-21 2018-07-20 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途
CN202410633579.9A Pending CN118846017A (zh) 2017-07-21 2018-07-20 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410633579.9A Pending CN118846017A (zh) 2017-07-21 2018-07-20 抗原呈递合成表面、共价官能化表面、活化t细胞及其用途

Country Status (11)

Country Link
US (2) US20200299351A1 (https=)
EP (2) EP3655027B1 (https=)
JP (2) JP2020528747A (https=)
KR (1) KR20200030593A (https=)
CN (2) CN111107871A (https=)
AU (1) AU2018304543A1 (https=)
CA (1) CA3070289A1 (https=)
IL (1) IL272151A (https=)
SG (1) SG11202000425QA (https=)
TW (1) TWI832820B (https=)
WO (1) WO2019018801A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799865B2 (en) 2015-10-27 2020-10-13 Berkeley Lights, Inc. Microfluidic apparatus having an optimized electrowetting surface and related systems and methods
IL263274B2 (en) 2016-05-26 2023-10-01 Berkeley Lights Inc Covalently adapted surfaces, kits and methods for their production and uses
CA3112813A1 (en) * 2018-09-21 2020-03-26 Berkeley Lights, Inc. Functionalized well plate, methods of preparation and use thereof
CN113366312A (zh) 2018-11-01 2021-09-07 伯克利之光生命科技公司 在微流体环境中测定生物细胞的方法
WO2020168258A1 (en) 2019-02-15 2020-08-20 Berkeley Lights, Inc. Laser-assisted repositioning of a micro-object and culturing of an attachment-dependent cell in a microfluidic environment
WO2020223555A1 (en) 2019-04-30 2020-11-05 Berkeley Lights, Inc. Methods for encapsulating and assaying cells
US20220204943A1 (en) * 2020-12-31 2022-06-30 Academia Sinica Cell culture systems, methods and uses thereof
US12275932B2 (en) * 2021-04-28 2025-04-15 A.U. Vista, Inc. TFT-based cell isolation device and cell manipulation panel thereof
WO2023161961A1 (en) * 2022-02-24 2023-08-31 Lymphon Biologics Pvt. Ltd. A system and method for t cell activation and immunomodulation
WO2025111584A1 (en) * 2023-11-22 2025-05-30 Georgia Tech Research Corporation An electronic microfluidic platform for on-chip apoptosis quantification using annexin v-based ps externalization detection

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000184880A (ja) * 1998-10-14 2000-07-04 Kanegafuchi Chem Ind Co Ltd ガン細胞特異的傷害性ｔ細胞の増殖・活性化誘導方法及びそれに用いるデバイス
US20020058019A1 (en) * 2000-02-24 2002-05-16 Ronald Berenson Simultaneous stimulation and concentration of cells
US20040072278A1 (en) * 2002-04-01 2004-04-15 Fluidigm Corporation Microfluidic particle-analysis systems
US20040224402A1 (en) * 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
EP1739166A1 (en) * 2005-07-01 2007-01-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population
US20120121649A1 (en) * 2010-11-12 2012-05-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US20150329617A1 (en) * 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
WO2016105542A2 (en) * 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
WO2016166568A1 (en) * 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
CN106459917A (zh) * 2014-04-23 2017-02-22 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
WO2017117521A1 (en) * 2015-12-31 2017-07-06 Berkeley Lights, Inc. Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP3926842B2 (ja) * 1995-03-08 2007-06-06 ザ・スクリプス・リサーチ・インステイチユート 抗原提示系およびｔ−細胞の活性化方法
US6294063B1 (en) 1999-02-12 2001-09-25 Board Of Regents, The University Of Texas System Method and apparatus for programmable fluidic processing
US6942776B2 (en) 1999-05-18 2005-09-13 Silicon Biosystems S.R.L. Method and apparatus for the manipulation of particles by means of dielectrophoresis
IL147302A0 (en) 1999-06-28 2002-08-14 California Inst Of Techn Microfabricated elastomeric valve and pump systems
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US6958132B2 (en) 2002-05-31 2005-10-25 The Regents Of The University Of California Systems and methods for optical actuation of microfluidics based on opto-electrowetting
US7612355B2 (en) 2004-04-12 2009-11-03 The Regents Of The University Of California Optoelectronic tweezers for microparticle and cell manipulation
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
CA2665568C (en) * 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
US8685344B2 (en) 2007-01-22 2014-04-01 Advanced Liquid Logic, Inc. Surface assisted fluid loading and droplet dispensing
WO2008119066A1 (en) 2007-03-28 2008-10-02 The Regents Of The University Of California Single-sided lateral-field and phototransistor-based optoelectronic tweezers
US20080241892A1 (en) * 2007-03-29 2008-10-02 Pacific Biosciences Of California, Inc. Modified surfaces for immobilization of active molecules
US9809797B2 (en) 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
US9533306B2 (en) 2010-08-02 2017-01-03 The Regents Of The University Of California Single sided continuous optoelectrowetting (SCEOW) device for droplet manipulation with light patterns
US9227200B2 (en) 2011-06-03 2016-01-05 The Regents Of The University Of California Microfluidic devices with flexible optically transparent electrodes
CA2858115A1 (en) * 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
US9857333B2 (en) 2012-10-31 2018-01-02 Berkeley Lights, Inc. Pens for biological micro-objects
US9403172B2 (en) 2012-11-08 2016-08-02 Berkeley Lights, Inc. Circuit based optoelectronic tweezers
AU2014245806B2 (en) 2013-03-28 2019-10-31 The University Of British Columbia Microfluidic devices and methods for use thereof in multicellular assays of secretion
WO2015051247A1 (en) * 2013-10-03 2015-04-09 University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells
US9889445B2 (en) 2013-10-22 2018-02-13 Berkeley Lights, Inc. Micro-fluidic devices for assaying biological activity
EP3060645B1 (en) 2013-10-22 2019-01-02 Berkeley Lights, Inc. Microfluidic devices having isolation pens and methods of testing biological micro-objects with same
CA2945177C (en) 2014-04-25 2021-12-21 Berkeley Lights, Inc. Providing dep manipulation devices and controllable electrowetting devices in the same microfluidic apparatus
US20150306599A1 (en) 2014-04-25 2015-10-29 Berkeley Lights, Inc. Providing DEP Manipulation Devices And Controllable Electrowetting Devices In The Same Microfluidic Apparatus
US20150306598A1 (en) 2014-04-25 2015-10-29 Berkeley Lights, Inc. DEP Force Control And Electrowetting Control In Different Sections Of The Same Microfluidic Apparatus
US10520251B2 (en) 2015-01-15 2019-12-31 Heraeus Noblelight America Llc UV light curing systems, and methods of designing and operating the same
WO2017124101A2 (en) 2016-01-15 2017-07-20 The Broad Institute Inc. Semi-permeable arrays for analyzing biological systems and methods of using same
DK3430131T3 (da) * 2016-03-17 2022-08-22 Berkeley Lights Inc Selektion og kloning af t-lymfocytter i en mikrofluidanordning
IL263274B2 (en) 2016-05-26 2023-10-01 Berkeley Lights Inc Covalently adapted surfaces, kits and methods for their production and uses

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000184880A (ja) * 1998-10-14 2000-07-04 Kanegafuchi Chem Ind Co Ltd ガン細胞特異的傷害性ｔ細胞の増殖・活性化誘導方法及びそれに用いるデバイス
US20020058019A1 (en) * 2000-02-24 2002-05-16 Ronald Berenson Simultaneous stimulation and concentration of cells
JP2004500095A (ja) * 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US20150329617A1 (en) * 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
US20040072278A1 (en) * 2002-04-01 2004-04-15 Fluidigm Corporation Microfluidic particle-analysis systems
US20040224402A1 (en) * 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
EP1739166A1 (en) * 2005-07-01 2007-01-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population
US20120121649A1 (en) * 2010-11-12 2012-05-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN106459917A (zh) * 2014-04-23 2017-02-22 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
WO2016105542A2 (en) * 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
WO2016166568A1 (en) * 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
WO2017117521A1 (en) * 2015-12-31 2017-07-06 Berkeley Lights, Inc. Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide

Also Published As

Publication number Publication date
EP4620977A3 (en) 2025-12-17
WO2019018801A1 (en) 2019-01-24
SG11202000425QA (en) 2020-02-27
EP3655027A4 (en) 2021-04-21
US20250051417A1 (en) 2025-02-13
KR20200030593A (ko) 2020-03-20
EP3655027A1 (en) 2020-05-27
JP2024020231A (ja) 2024-02-14
EP3655027B1 (en) 2025-09-03
CA3070289A1 (en) 2019-01-24
IL272151A (en) 2020-03-31
EP4620977A2 (en) 2025-09-24
TW201908336A (zh) 2019-03-01
US20200299351A1 (en) 2020-09-24
TWI832820B (zh) 2024-02-21
WO2019018801A8 (en) 2020-09-10
AU2018304543A1 (en) 2020-02-13
JP2020528747A (ja) 2020-10-01
CN118846017A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
US20250051417A1 (en) Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof
US20220325240A1 (en) Systems, apparatuses, and methods for cellular therapeutics manufacture
US20240342704A1 (en) Proto-Antigen-Presenting Synthetic Surfaces, Activated T Cells, and Uses Thereof
JP6902548B2 (ja) 患者特異的抗癌治療剤の製造方法及びその治療方法
JP7287782B2 (ja) マイクロ流体デバイスにおけるｔリンパ球の選択及びクローニング
JP7038100B2 (ja) マイクロ流体デバイスでのｔリンパ球の選別
HK40029089A (en) Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated t cells, and uses thereof
US12545878B2 (en) Systems and apparatuses for cellular therapeutics manufacture
US20240272171A1 (en) Methods for Identification of Exchangeable MHC Binding Peptides and Methods of Use Thereof
HK40048177A (en) Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
CN117015597A (zh) 用于细胞治疗剂制造的系统、装置和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029089

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20200505

RJ01 Rejection of invention patent application after publication